Wide Ranks

CTMX

CytomX Therapeutics, Inc.

1.02

Top Statistics
Market Cap 79 M Forward PE -2.67 Revenue Growth 26.70 %
Current Ratio 1.04 Trailing PE 6.38 Earnings Growth 81.90 %
Profit Margins 10.92 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.18 Enterprise / Revenue -0.2150 Price To Sales Trailing12 Months 0.6304
Profitability
Profit Margins 10.92 % Operating Margins 12.30 %
Balance Sheet
Total Cash 117 M Total Cash Per Share 1.50 Total Debt 10 M
Total Debt To Equity Current Ratio 1.04 Book Value Per Share -0.3000
All Measures
Short Ratio 441.00 % Message Board Id finmb_60504284 Fax 650 351 0353
Shares Short Prior Month 6 M City South San Francisco Uuid c5953a3e-48a3-3ef1-b8e7-58afa2ecd58e
Previous Close 1.02 First Trade Date Epoch Utc 1 B Book Value -0.3000
Beta 1.06 Total Debt 10 M Volume 371435
Fifty Two Week Low 0.8330 Total Cash Per Share 1.50 Total Revenue 126 M
Shares Short Previous Month Date 1 B Target Median Price 3.68 Max Age 86400
Recommendation Mean 2.14 Sand P52 Week Change 0.3133 Operating Margins 12.30 %
Target Mean Price 5.29 Net Income To Common 13 M Short Percent Of Float 0.0571
Implied Shares Outstanding 78 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 845740 Average Volume10days 845740 Total Cash 117 M
Next Fiscal Year End 1 B Revenue Per Share 1.52 Held Percent Insiders 0.0100
Ebitda Margins 6.75 % Trailing PE 6.38 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.02 Target Low Price 3.25
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.07 Open 1.02
Free Cashflow -13728250 State CA Dividend Yield 0.00 %
Return On Assets 0.0233 Time Zone Short Name EST Trailing Eps 0.1600
Day Low 0.9900 Address1 151 Oyster Point Boulevard Shares Outstanding 78 M
Price Hint 4 Target High Price 8.00 Website https://www.cytomx.com
52 Week Change -0.2662 Average Volume 821025 Earnings Quarterly Growth 91.70 %
Forward Eps -0.5800 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 101.40 % Is_sp_500 False Regular Market Day High 1.03
Profit Margins 10.92 % Fifty Two Week High 5.85 Day High 1.03
Shares Short 4 M Regular Market Open 1.02 Industry Key biotechnology
Earnings Growth 81.90 % Enterprise To Revenue -0.2150 Revenue Growth 26.70 %
Shares Percent Shares Out 0.0567 Operating Cashflow -88286000 Currency USD
Time Zone Full Name America/New_York Market Cap 79 M Is_nasdaq_100 False
Zip 94080 Quote Type EQUITY Industry Biotechnology
Long Name CytomX Therapeutics, Inc. Regular Market Day Low 0.9900 Held Percent Institutions 0.6562
Current Price 1.02 Address2 Suite 400 Enterprise To Ebitda -3.18
Financial Currency USD Current Ratio 1.04 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 66 M Two Hundred Day Average 1.58 Enterprise Value -27166944
Price To Sales Trailing12 Months 0.6304 Forward PE -2.67 Regular Market Volume 371435
Ebitda 8 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.

The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.

In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.

It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.